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Abstract
There is an urgent need to apply basic research achievements to the clinic. In particu-
lar, mechanistic studies should be developed by bench researchers, depending upon
clinical demands, in order to improve the survival and quality of life of cancer
patients. To date, translational medicine has been addressed in cancer biology, par-
ticularly in the identification and characterization of novel tumor biomarkers. This
review focuses on the recent achievements and clinical application prospects in
tumor biomarkers based on translational medicine.
Introduction
For decades, research on life science has made major break-
throughs, including the discovery of stem cells and comple-
tion of human genome sequencing, which have great
significance in the promotion of medical research progress.
However, few basic research findings have actually been
applied to clinics for the benefit of patients. A new model of
research, translational medicine, has been introduced to fill
the gap between basic research and clinical application.1–3 It is
a two-way, open circulation research system, from bench to
bedside and frombedside to bench.4,5 The translationalmedi-
cine research model has become a strategy direction for the
field of biomedical research.
Translational medicine plays an important role in the
research of malignant tumors and clinical treatment.6 Malig-
nant tumors have become the leading cause of death in the
Chinese population. Although basic research on tumor
biology has broadened our understanding of factors such as
occurrence, metastasis, and drug resistance, care of cancer
patients is generally by indiscriminate treatment, that is,
patients are given the same treatment without fully consider-
ing their individual biological characteristics; thus, the
general survival rate has not significantly improved in the last
20 years.7 Tumor biomarkers are of potential use in early
cancer diagnosis, anticancer therapy development, and
monitoring the response to treatment. We provide a mini-
review of recent advances in tumor biomarkers based on
translational medicine.
Research development and clinical
application of tumor biomarkers
Concepts of tumor biomarkers
Tumor biomarkers are substances present in or produced by a
tumor itself or by the host microenvironment in response to
the process of tumorigenesis and progression. They cover a
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broad range of biochemical entities, such as proteins, hor-
mones, enzymes, and oncogene products. These substances
can be found in cells, tissues, or body fluids, and can be quali-
tatively or quantitatively detected by chemical, immunologi-
cal, andmolecular biological techniques.8 Tumor biomarkers
represent an effective tool for tumor diagnosis, treatment,
prognosis, and therapeutic monitoring.9 The Early Detection
Research Network (EDRN) is a large network project in
translational research sponsored by the United States
National Cancer Institute (NCI). This project mainly focuses
on early tumor diagnosis, metastasis and relapse detection,
prognosis, and targeted therapy.
Tumor biomarkers in clinical application
As a key to individual medical treatment, research on tumor
biomarkers has increasingly gained attention. However, the
clinical application of tumor biomarkers is somewhat
limited.To date, only 20 types of tumor biomarkers have been
used in the clinical setting. Some of these markers are con-
fined to a certain type of cancer, while others exist in two or
more types of tumors; however, there is no“universal” tumor
marker present in all types of cancer.According to the chemi-
cal nature of tumor markers, they can be divided into six
types: oncofetal antigens (carcino-embryonic antigens
[CEA], alpha fetoprotein [AFP]), carbohydrate antigens
(CA125, CA15.3, etc.), enzymes (prostate-specific, neuron
specific enolase, etc.), hormones (human chorionic gonado-
tropin, calcitonin, etc.), proteins (ceruloplasmin, etc.) and
genes (P53, V-KI-ras2 Kirsten rat sarcoma viral oncogene
homolog [KRAS], etc.). Tumor biomarkers commonly used
in the clinical setting are summarized in Table 1.
Latest progress of molecular biomarkers
of tumors
Tumor screening and early diagnosis
Conventional tumor biomarkers include tumor antigens and
differentially expressed gene products, such as breast cancer
1, early onset (BRCA1) and BRCA2.61 Researchers from
Peking University recently reported that the reproducibility
of cancer-specific copy number variation (CNV) offers
potential for noninvasive circulating tumor cell (CTC)-based
cancer diagnostics.62 Kinde et al. performed whole genome
sequencing on cervical secretions for ovarian and endome-
trial cancer diagnosis, and established suitable routine
screening methods for these tumors.63 Wang et al. suggested
that Hsp90a is a potential tumor biomarker.64 Recent discov-
eries have shown that micro ribonucleic acid (miRNA) is
stable in serumand can enter peripheral circulation; thus, cir-
culating miRNA may be used as a biological tumor marker
for early diagnosis. Harris et al. reported that miR-375
expression level was closely related to the death rate of
patients with head and neck cancer, and can, thus, be
regarded as a novel tumor biomarker.65 In 2014, Ribeiro et al.
proposed that miR-125b might serve as a predictive
biomarker for the occurrence of cervical cancer and that
MiR-34a might be regarded as a potential biomarker
for further development.66 Kelber et al. reported that
pseudopodium-enriched atypical kinase 1 (PEAK1) was a
novel biomarker for the early prediction of pancreatic
cancer.67 These findings are expected to be applied to early
diagnosis and screening if results from a large number of
clinical specimens can be validated.
Table 1 Summary of commonly used tumor biomarkers
Molecular markers Types of tumors
AFP Hepatocellular carcinoma, germ cell
tumors10,11
ALK Non-small cell lung cancer, anaplastic
large cell lymphoma12,13
B2M Multiple myeloma, chronic lymphocytic
leukemia14,15
BCR-ABL Chronic myelogenous leukemia16
BRAF mutation V600E Cutaneous melanoma, colorectal
cancer17,18
β-HCG Choriocarcinoma, testicular cancer19
CA125, HE4, ROMA, OVA1 Ovarian cancer20
CA15.3, CA549, MCA
CA27.29, Her-2/neu, ER/PR,
uPA, PAI-1, 21-Gene
signature, 70-Gene
signature
Breast cancer21–27
CA19-5 colorectal cancer28
CA19-9, CA50 Pancreatic cancer, gallbladder cancer, bile
duct cancer, gastric cancer29–34
CA242 gastrointestinal tract cancer, pancreatic
cancer35,36
CA72-4 Gastric cancer, pancreatic cancer37,38
Calcitonin Medullary thyroid carcinoma39
CEA Breast cancer,22 pancreatic cancer29
colorectal cancer40
CD20 Non-Hodgkin lymphoma41
CgA Neuroendocrine tumor42
DU-PAN-2 Pancreatic cancer, endometrial cancer43,44
EGFR, CYFRA 21-1 Non-small cell lung cancer45,46
FDP, NMP22, Chromosomes
3, 7, 17, and 9p21
Bladder cancer47–49
HAb18G/CD147 Hepatocellular carcinoma50
IPO-38 Gastric cancer51
KIT Gastrointestinal stromal tumor, mucosal
melanoma52,53
KRAS Colon cancer, non-small cell lung
cancer54,55
Lactate dehydrogenase Germ cell tumor56
PSA, PAP, PCA3 Prostate cancer57,58
Thyroglobulin, galectin-3 Thyroid cancer59,60
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Tumor deterioration biomarkers: Metastasis,
recurrence, and drug resistance
Metastasis is one of the primary causes of death in cancer
patients. When tumor metastasis occurs, the routine clinical
treatment outcome is poor, resulting in high mortality;
however,when a tumor is diagnosed,many patients face over-
treatment with feasible side effects because there is no
optional way to determine whether there is a metastasis.
According to statistics, 20∼25% of patients diagnosed with
lymph node-negative breast cancer will experience tumor
metastasis in the 10 years after surgery, but asmany as 90% of
patients receive postoperative systemic chemotherapy.68 It is
very important to learn how we can more accurately deter-
mine the probability of tumor metastasis, and choose rel-
evant treatments with fewer side effects. Early diagnosis of
tumors can help patients receive timely and effective treat-
ment. Early diagnosis and prediction of tumormetastasis can
also provide more detailed and reliable tumor information
for doctors. Itmay help doctors to decidewhether further sys-
temic treatment is needed and choose appropriate clinical
treatment after primary tumor resection, in order to improve
patients’ quality of life and prolong survival.
Some tumor biomarkers may become better predictors of
tumor recurrence and metastasis because their abnormal
expression often occurs earlier than other detection signs,
such as clinical imaging or symptoms. They may also be used
to predict the tumor response to different treatments and
evaluate prognosis. Dynamic monitoring serums AFP after
hepatocellular carcinoma surgery and CEA after colorectal
cancer can be adopted for early diagnosis of recurrence and
metastasis. Chen et al. reported that serum cholinergic mus-
carinic 2 receptor (CHRM2), family with sequence similarity
5, member C (FAM5C), and promoter hypermethylation of
myosin light chain kinase (MYLK) were considered gastric
cancer markers, because their serum levels significantly
decreased after tumor resection; these findings can be used to
evaluate the effect of surgery and prognosis.69 Recently, Tsai
et al. observed that a higher serum level of miR-196 corre-
lated with the recurrence of gastric cancer in gastric cancer
patients.70 Budhu et al. found that the expression of a
20-miRNA signature had important significance for identify-
ing hepatocellular carcinoma patients who are likely to
develop metastases and recurrence.71 Lu et al. also reported
that a rise in chemokine CCL2 level might be an important
indicator for bonemetastasis in prostate and lung cancers.72–74
Tumor prognostic biomarkers
The application of molecular markers means that tumor
prognosis assessment is no longer confined to clinical patho-
logical parameters.Markers can more accurately assess prog-
nosis by classifying molecular signatures. Mahmoud et al.
observed that the number of breast tumor-infiltrating CD8+
T lymphocytes was positively correlated with survival period;
therefore, it can be considered as an evaluation indicator for
the prognosis of breast cancer patients.75 Winter et al. found
that pancreatic cancer patients with higher expressions of
signal transducer activator of transcription 3 (STAT3), FBJ
murine osteosarcoma viral oncogene homolog (FOS), and
jun proto-oncogene (JUN) have relatively shorter survival
periods. Those with a higher expression of specificity protein
1 (SP1), caudal-type homeobox transcription factor 2
(CDX2), CCAAT/enhancer binding protein alpha (CEBPA)
andBRCA1have relatively longer survival periods.Therefore,
these seven genes combined with pathological parameters
can accurately classify patients into good and poor prognosis
groups, and help to determine whether adjuvant therapy is
needed.76 Lee et al. selected 27 proteins related to the progno-
sis of gastric cancer from 56 genes, based on which patients
were divided into two types.Type I tended to be intestinal and
early, with a better prognosis than type II; the prognostic
accuracy reached 73% or more.77 Moreira et al. reported that
neuronal PAS domain protein 3 (NPAS3) drives the progres-
sion of human malignant astrocytomas as a tumor suppres-
sor and is a negative prognostic marker for survival.78 A
uniquemetastatic gene signature enables prediction of tumor
relapse in early stage hepatocellular carcinoma patients.79
Viral-derived biomarkers of tumor
In recent years, virus-derived DNA,messenger (m)RNA, and
proteins, as biomarkers for virus-associated tumors, have
beenwidely used in different clinical applications in theman-
agement of tumors, including screening, monitoring, and
prognostication. Therefore, the analysis of virus-derived
DNA, mRNA and proteins is expected to become an impor-
tant tool in the management of cancer in the near future.
Epstein-Barr virus (EBV) infection is an important etiol-
ogy for nasopharyngeal carcinoma (NPC), as the EBV
genome can be detected in almost all NPC tumor tissues.80
Plasma EBV-DNA, when quantitatively analyzed using real-
time polymerase chain reaction, has been developed as a
biomarker for NPC.81 In addition, as a result of excellent sen-
sitivity and specificity, plasma EBV-DNA can also be used as a
non-invasive biomarker for EBV-positive Hodgkin’s lym-
phoma; serialmonitoring could predict response to therapy.82
Recent research has indicated that autoantibody signatures
combined with EBV capsid antigen-IgA (VCA-IgA), as a
biomarker panel of NPC,might aid in the screening and diag-
nosis of NPC.83 Nishino et al. revealed that a high serum level
of Epstein-Barr virus–induced gene 3 (EBI3), as an indepen-
dent prognostic factor,was associatedwith a poor lung cancer
prognosis, suggesting that EBI3 is a potential serum and
tissue biomarker, as well as therapeutic target for lung
cancer.84 Epidemiological studies have emphasized that the
H. Guo et al. Recent advances in tumor biomarkers
Thoracic Cancer 6 (2015) 665–671 © 2015 The Authors. Thoracic Cancer published by China Lung Oncology Group and Wiley Publishing Asia Pty Ltd 667
human papillomavirus (HPV) is the main etiological factor
for cervical cancer and DNA of specific HPV types has been
found in almost all cervical cancer biopsies.85 Attributing to
its highly sensitivity, accuracy, and reliability, HPV DNA
testing has become a powerful screening tool for the second-
ary prevention of cervical cancer.86–89 In addition to high-risk
HPV-DNA, the constitutive expression of the viral oncogenes
E6 and E7 is another characteristic of cervical cancer.90 Dürst
et al. demonstrated that HPV-E6-E7-mRNA could be used as
a molecular marker for disseminated cervical cancer in order
to predict the risk of recurrence.91 Moreover, compared with
the HPV-DNA test, RNA-based HPV assay was more specific
and sensitive for the detection of high-grade pre-cancerous
lesions and may be used in primary cervical cancer screening
for women 30 years and older.92
Tumor biomarkers for targeted therapy
The intervention of some tumor related genes was observed
to achieve anti-tumor effects. This so-called “targeted
therapy” provides a new method for tumor management.
Molecules for targeted therapy can be divided into the follow-
ing categories: oncogenes and tumor suppressor genes (c-Ras
and p53), epidermal growth factor receptor (EGFR), the key
protein kinase of signal transduction (PI3K), nuclear tran-
scription factor κB (NF-κB), transmethylase or histone
deacetylase (HDAC), and tumor angiogenesis related mol-
ecules.93,94 Targeted therapeutic options include small
molecular compounds, antibodies, recombinant virus
vectors and small interfering (si)RNAs. For example, the
monoclonal antibody trastuzumab interferes with human
epidermal growth factor 2 (HER2)/neu over-expression in
breast cancer; the small molecule inhibitor imatinib is used
for break point cluster/Abelson (BCR/ABL) gene rearrange-
ment in chronic myeloid leukemia, caused by chromosomal
translocations; the small molecule inhibitor erlotinib for
EGFR-mutated lung cancer; and promyelocytic leukemia
(PML)-retinoic acid receptor (RAR) alpha, a fusion protein
containing sequences from the PML zinc finger protein and
RAR alpha, as a direct drug target in arsenic treatment for
acute PML.95
Cho-Park and Stellar recently reported an adipose-ribosyl
transferase, tankyrase (TNKS), could promote 26S pro-
teasome activity, and a small-molecule inhibitor, XAV939,
could inhibit TNKS activity and block proteasome activity,
which suggests that a small molecule could be used in the
treatment of multiplemyeloma.96 Emerling et al. showed that
a subset of breast cancers express higher levels of the type 2
phosphatidylinositol-5-phosphate 4-kinases α and/or β
(PI5P4Kα and β) and provided evidence that these kinases
are essential for growth in the absence of p53. They also indi-
cated that inhibitors of PI5P4Ks could be effective in prevent-
ing or treating cancers with mutations in p53.97 Leprivier
et al. discovered a protein, eEF2K, which is not important in
normal cells but essential in cancer cells; thus, blocking the
function of eukaryotic elongation factor-2 kinase (eEF2K)
can effectively kill cancer cells without affecting the biological
process of normal cells. Therefore, blocking the protein is
expected to be significant in the treatment of cancer.98
Clinical application prospects of
tumor biomarkers
Research on molecular markers of tumors has made great
progress in recent years. Tumor biomarkers with potential
diagnostic and therapeutic value are accumulating.However,
it is important to direct cancer research on diagnosis and
treatment toward applying these fundamental research find-
ings to the clinic as soon as possible, and applying novel
tumor molecular markers to early diagnosis, targeted
therapy, and individualized treatment. Excessive medical
treatment should be avoided through the analysis of new
tumor biomarkers and appropriate treatments. A large data-
base of clinical specimens to validate new tumor biomarkers
is required; therefore, a worldwide EDRN system should be
established and a series of standards in the process from
tumor biomarker discovery to clinical application should be
set.
Conclusion
Translational research on tumor biomarkers has successfully
promoted the development of tumor treatment and has
brought new hope for cancer patients. As the concept of
translational medicine is carried into the field of clinical
medicine and basic research, particular emphasis needs to be
directed to clinical application, which, in turn, will provide
feedback to researchers in order to improve solutions and
serve patients.
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